Hwanin Benztropine Tablet (Benztropine Mesilate)

Key information summary

Efficacy & effects

This medication is used to treat idiopathic Parkinson's disease, Parkinsonism caused by post-encephalitis or atherosclerosis, and Parkinson's disease due to antipsychotic drug administration.

Dosage

For oral administration, the initial dose is 0.5-1 mg per day of benzotropine mesylate. Gradually increase the dose by 0.5 mg per day at intervals of 5-6 days to reach a maintenance dose. The maintenance dose is determined considering improvement of symptoms and occurrence of side effects and does not exceed 6 mg per day. Adjust according to age and symptoms. For injection, the initial dose is 0.5-1 mg per day of benzotropine mesylate administered intramuscularly or intravenously.

Precautions

This medication should not be used in patients with glaucoma, those allergic to this medication, patients with myasthenia gravis, and children under 3 years old. Additionally, it contains lactose, so it should not be administered to patients with genetic issues such as galactose intolerance, Lapp lactase deficiency, or glucose-galactose absorption disorders. Patients with obstructive urinary diseases such as benign prostatic hyperplasia, those with arrhythmias or tachycardia, patients with liver or kidney dysfunction, the elderly, children over 3 years old, and those in hot environments should use this medication cautiously. When taking this medication, central nervous system symptoms such as movement control disorders, mental confusion, hallucinations, consciousness disorders, delirium, irritability, anxiety, depression, lethargy, and sensory abnormalities in the hands and feet may occur. Gastrointestinal symptoms such as dry mouth, nausea, vomiting, and constipation may also arise. In the urinary system, difficulties in urination or urinary retention may occur. If skin rashes appear as an allergic reaction, discontinuation of this medication is necessary. Eye control disorders may also occur, so caution is required. This medication should be started at a low dose and gradually increased while monitoring the condition. When switching from another medication to this one, it is safe to gradually decrease the existing medication while gradually increasing this one. Regular eye examinations and intraocular pressure tests are recommended during administration. Unlike some other anti-Parkinson medications, this medication may not alleviate involuntary movements around the mouth, and may even worsen symptoms. Moreover, it may reduce attention, concentration, and reflexes, so driving a car or operating hazardous machinery should be avoided during treatment. This medication may enhance its efficacy when used together with phenothiazine derivatives, tricyclic antidepressants, MAO inhibitors, or reserpine derivatives, so caution is advised. Moreover, concomitant use with anticholinergic drugs can lead to symptoms of intestinal paralysis (anorexia, nausea, vomiting, severe constipation, abdominal distention, etc.) and in this case, administration should be stopped. These symptoms may be masked by the emetic effect, so careful observation is necessary. It is advisable to avoid administering this medication to pregnant or potentially pregnant women and nursing mothers, as its safety has not been established.

Side effects

Ataxia, mental confusion, hallucinations, consciousness disorders, delirium, irritability, agitation, anxiety, depression, lethargy, sensory disturbances of the limbs, dry mouth, nausea, vomiting, constipation, urinary difficulties, urinary retention, rashes, control disturbances.

Alternatives / Same-ingredient medications

• 

  Myungin Benztropine Mesylate Tablet 2 mg

  Same ingredient
• 

  Myungin Benztropine Mesylate Tablet 1 mg

  Same ingredient
• 

  Hwanin Benztropine Tablet 1 mg (Benztropine Mesylate)

  Same ingredient

Related searches